¿ Neomorphic Inc., of Berkeley, Calif., said it has shortened its name from Neomorphic Software Inc. and changed its focus to the formation and implementation of drug discovery collaborations with pharmaceutical and biotechnology industry partners.
¿ PPD Discovery Inc., of Wilmington, N.C., acquired the assets of the Pharmazyme division of Immune Complex Corp., of San Diego. Pharmazyme is a leading developer, producer and marketer of drug metabolism reagent products and services.
¿ Synsorb Biotech Inc., of Calgary, Alberta, signed a marketing and distribution agreement for Synsorb Pk in the Netherlands, Belgium and Luxembourg with Tramedico International BV, of the Netherlands. Synsorb will supply the product and Tramedico will be responsible for all costs associated with distribution, marketing and sale of the product in the three countries. Tramedico will provide Synsorb with an undisclosed up-front payment, milestone payments and a share of sales revenue.
¿ Unigene Laboratories, of Fairfield, N.J., completed testing of the clinical supplies of oral calcitonin that will be used by Warner-Lambert Co., of Morris Plains, N.J., in its upcoming Phase I/II study. Unigene received a $1 million payment from Warner-Lambert for achieving the milestone.
¿ UroGenesys Inc., of Santa Monica, Calif., and Protein Pathways Inc., of Los Angeles, formed an alliance to apply Protein Pathways¿ proprietary bioinformatics technologies to UroGenesys¿ proprietary database of cancer-associated antigens. The companies expect the combination of their genomics and proteomics expertise to uncover functional information to guide therapeutic development of UroGenesys¿ proprietary antigens, and to identify new product candidates for cancer therapy. Terms of the alliance were not disclosed.
¿ ViroPharma Inc., of Exton, Pa., and Madison, N.J.-based American Home Products Corp., through its Wyeth-Ayerst Laboratories division, initiated clinical trials with a new compound to treat hepatitis C. The trials are being conducted in the UK and are designed to evaluate the safety of the compound in healthy volunteers. Also, the company increased its previously announced private placement of convertible subordinated notes due 2007 to $150 million, pricing the offering at $109.15 per share. The offering is expected to close Wednesday. ViroPharma also granted the initial purchasers an option to purchase up to an additional $30 million in principal amount of the notes. The company had intended to raise $100 million through the offering. (See BioWorld Today, Feb. 17, 2000, p. 5.)
¿ ReGen Biologics Inc., of Franklin Lakes, N.J., said it received marketing clearance in Europe for its Collagen Meniscus Implant (CMI). ReGen plans to launch the product through its distribution partnership with SulzerMedica, of Barr, Switzerland. The CMI is used in treating tears of the meniscus of the knee.